Transforming growth factor beta (TGF-.beta.) blocking agent-treated stem cell composition and method
Patent Number: 6841542
Date of First Priority Issue: Thursday July 6th, 2000
Date Issued: Tuesday January 11th, 2005
Assignee: AVI BioPharma, Inc. (Corvallis, OR)
Inventors: Bartelmez, Stephen H. (Seattle, WA); Iversen, Patrick L. (Corvallis, OR)
From Class: Expansion
Comments: No comments
This patent claims ex vivo inhibition of TGF beta in hematopoietic stem cells in order to increase speed of engraftment post recipient marrow ablation.
Since TGF beta is an endogenous inhibitor of stem cell proliferation, the inhibition of the inhibitor should lead to enhanced proliferation.
The technology described in this patent would definately benefit from RNA interference.
Unfortunately, clinical implimentation may be risking due to potential for increasing incidence of leukemia.
View this patent on the USPTO website.
Added to StemCellPatents.com on Monday October 16th, 2006
Social & Bookmarking:
Add Comment
You must be signed-in to add your comments.
Sign-in now or Join the StemCellPatents.com Community for free.